Clinical Trial Update: A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating safety and efficacy of duvelisib in relapsed/refractory follicular lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Follicular Lymphoma | Phase 2 | Status: UNKNOWN